BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...
U.S. health officials have added two deadly rare diseases to the list of conditions the government recommends states screen ...
Pharmaceutical Technology on MSN
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue ...
Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...
Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...
Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel ...
MS. JOHNSON: Hello, and welcome to Post Live. I’m Akilah Johnson, a national health reporter focused on health disparities here at The Washington Post. And today we have two segments on rare diseases.
When his infant son was diagnosed with a rare disease, a Canadian father was dismayed to discover there was no treatment or cure. So he set out to make one himself. Terry Pirovolakis, an IT director ...
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback